Tom 14, Nr 3 (2017)
Farmakoterapia chorób układu krążenia
Opublikowany online: 2017-10-23

dostęp otwarty

Wyświetlenia strony 504
Wyświetlenia/pobrania artykułu 13814
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Rejestracyjne i pozarejstracyjne wskazania do stosowania iwabradyny — u jakich pacjentów iwabradyna może przynosić korzyści?

Filip M. Szymański1
Choroby Serca i Naczyń 2017;14(3):128-134.

Streszczenie

Iwabradyna jest lekiem wyjątkowym, ponieważ jako jedyny lek selektywnie obniża częstość rytmu serca. Stosowanie iwabradyny łączy się z wieloma korzystnymi działaniami wyrażonymi przede wszystkim ko­rzystnym wpływem na rokowanie pacjentów, nie tylko w typowej sytuacji niewydolności serca, ale także u chorych, których nie ujęto dotychczas w wytycznych — w tak zwanych sytuacjach off-label. Poniższe opracowanie stanowi podsumowanie sylwetek pacjentów, u których stosowanie iwabradyny przynosi korzyści.

Iwabradyna jest lekiem wyjątkowym, ponieważ jako jedyny lek selektywnie obniża częstość rytmu serca. Stosowanie iwabradyny łączy się z wieloma korzystnymi działaniami wyrażonymi przede wszystkim korzystnym wpływem na rokowanie pacjentów, nie tylko w typowej sytuacji niewydolności serca, ale także u chorych, których nie ujęto dotychczas w wytycznych — w tak zwanych sytuacjach off-label. Poniższe opracowanie stanowi podsumowanie sylwetek pacjentów, u których stosowanie iwabradyny przynosi korzyści.

Referencje

  1. Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012; 17(5): 4924–4935.
  2. Manz M, Reuter M, Lauck G, et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003; 100(3): 149–155.
  3. Canet E, Lerebours G, Vilaine JP. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. Ann NY Acad Sci. 2011; 1222: 90–99.
  4. Corlanor [package insert]. Amgen Inc., Thousand Oaks 2015.
  5. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875–885.
  6. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005; 26(10): 967–974.
  7. Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012; 59(22): 1938–1945.
  8. Bocchi EA, Böhm M, Borer JS, et al. SHIFT investigators. Effect of combining ivabradine and β-blockers: focus on the use of carvedilol in the SHIFT population. Cardiology. 2015; 131(4): 218–224.
  9. Kosmala W, Holland DJ, Rojek A, et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013; 62(15): 1330–1338.
  10. Oliphant CS, Owens RE, Bolorunduro OB, et al. Ivabradine: a review of labeled and off-label uses. Am J Cardiovasc Drugs. 2016; 16(5): 337–347.
  11. Kasprzak JD, Stępińska J, Wożakowska-Kapłon B, et al. Optymalna częstość rytmu serca — aktualny cel terapii kardiologicznej. Stanowisko grupy ekspertów Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol Pol. 2012; 70: 1081–1094.
  12. Böhm M, Reil JC. Heart rate: surrogate or target in the management of heart failure? Heart. 2013; 99(2): 72–75.
  13. Biel M, Wahl-Schott C, Michalakis S, et al. Hyperpolarization-activated cation channels: from genes to function. Physiol Rev. 2009; 89(3): 847–885.
  14. Palatini P. Elevated heart rate: a "new" cardiovascular risk factor? Prog Cardiovasc Dis. 2009; 52(1): 1–5.
  15. Jurca R, Jackson AS, LaMonte MJ, et al. Assessing cardiorespiratory fitness without performing exercise testing. Am J Prev Med. 2005; 29(3): 185–193.
  16. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984; 226(4671): 180–182.
  17. Bassiouny HS, Zarins CK, Kadowaki MH, et al. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg. 1994; 19(3): 426–434.
  18. Albaladejo P, Carusi A, Apartian A, et al. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res. 2003; 40(4): 320–328.
  19. Mircoli L, Mangoni AA, Giannattasio C, et al. Heart rate-dependent stiffening of large arteries in intact and sympathectomized rats. Hypertension. 1999; 34(4 Pt 1): 598–602.
  20. Gillum RF, Mussolino ME, Makuc DM, et al. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 1991; 121(1 Pt 1): 172–177.
  21. Kannel WB, Kannel C, Paffenbarger RS, et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987; 113(6): 1489–1494.
  22. Custodis F, Reil JC, Laufs U, et al. Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol. 2013; 62(3): 183–187.
  23. Carnethon MR, Yan L, Greenland P, et al. Resting heart rate in middle age and diabetes development in older age. Diabetes Care. 2008; 31(2): 335–339.
  24. Shigetoh Y, Adachi H, Yamagishi Si, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens. 2009; 22(2): 151–155.
  25. Levy RL, White PD, Stroud WD, et al. Transcient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA. 1945; 129(9): 585–588.
  26. Palatini P, Thijs L, Staessen JA, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002; 162(20): 2313–2321.
  27. Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010; 55(2): 567–574.
  28. Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010; 31(18): 2271–2279.
  29. Al Bannay R, Böhm M, Husain A. Heart rate differentiates urgency and emergency in hypertensive crisis. Clin Res Cardiol. 2013; 102(8): 593–598.
  30. Tardif JC, Ford I, Tendera M, et al. INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005; 26(23): 2529–2536.
  31. Fox K, Ford I, Steg PG, et al. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9641): 807–816.
  32. Fox K, Ford I, Steg PG, et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014; 371(12): 1091–1099.
  33. Schulze V, Steiner S, Hennersdorf M, et al. Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology. 2008; 110(3): 206–208.
  34. Retegui G, Quintero M, Ruiz-Borrell M, et al. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol. 2009; 62(5): 577–579.
  35. Winum PF, Cayla G, Rubini M, et al. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin Electrophysiol. 2009; 32(7): 942–944.
  36. Sette A, Martino A, Lioy E, et al. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction. J Cardiovasc Electrophysiol. 2010; 21(7): 815–817.
  37. Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012; 60(15): 1323–1329.
  38. Ptaszynski P, Kaczmarek K, Ruta J, et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013; 15(1): 116–121.
  39. Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013; 18(4): 338–344.
  40. Cademartiri F, Mollet NR, Runza G, et al. Diagnostic accuracy of multislice computed tomography coronary angiography is improved at low heart rates. Int J Cardiovasc Imaging. 2006; 22(1): 101–5; discussion 107.
  41. Abbara S, Arbab-Zadeh A, Callister TQ, et al. SCCT guidelines for performance of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2009; 3(3): 190–204.
  42. Pichler P, Pichler-Cetin E, Vertesich M, et al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. Am J Cardiol. 2012; 109(2): 169–173.
  43. Celik O, Atasoy MM, Ertürk M, et al. Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy. Acta Radiol. 2014; 55(6): 676–681.
  44. Böhm M, Robertson M, Ford I, et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT trial). Am J Cardiol. 2015; 116(12): 1890–1897.
  45. Mahmoud K, Kassem HH, Baligh E, et al. The effect of ivabradine on functional capacity in patients with chronic obstructive pulmonary disease. Clin Med (Lond). 2016; 16(5): 419–422.
  46. Andrikopoulos G, Pastromas S, Kartalis A, et al. Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease. The RYTHMOS study. Hellenic J Cardiol. 2012; 53(2): 118–126.